Literature DB >> 33552540

Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study.

Giovanni Tarantino1, Felice Crocetto2, Concetta Di Vito2, Raffaele Martino2, Savio Domenico Pandolfo2, Massimiliano Creta2, Achille Aveta2, Carlo Buonerba3, Ciro Imbimbo2.   

Abstract

BACKGROUND: Since prostate-specific antigen (PSA) levels can be influenced by some routinely available clinical factors, a retrospective study was conducted to explore the influence of obesity, smoking habit, heavy drinking and chronic obstructive pulmonary disease on PSA levels in men with histologically confirmed prostate cancer. PATIENTS &
METHODS: We reviewed the medical records of 833 prostate cancer patients undergoing radical prostatectomy.
RESULTS: Serum PSA levels at the time of surgery were not associated with either BMI or history of chronic obstructive pulmonary disease or heavy drinking. Conversely, PSA levels were associated with smoking status.
CONCLUSION: Among the clinical factors explored in this homogeneous population, only tobacco use was associated with PSA levels, which should be considered when using PSA-based screening in male smokers.
© 2021 Felice Crocetto.

Entities:  

Keywords:  BMI; COPD; Gleason score; heavy drinking; smoking habit; total PSA

Year:  2021        PMID: 33552540      PMCID: PMC7849947          DOI: 10.2144/fsoa-2020-0154

Source DB:  PubMed          Journal:  Future Sci OA        ISSN: 2056-5623


  38 in total

Review 1.  Smoking and prostate cancer.

Authors:  K Hickey; K A Do; A Green
Journal:  Epidemiol Rev       Date:  2001       Impact factor: 6.222

2.  Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States).

Authors:  J R Cerhan; J C Torner; C F Lynch; L M Rubenstein; J H Lemke; M B Cohen; D M Lubaroff; R B Wallace
Journal:  Cancer Causes Control       Date:  1997-03       Impact factor: 2.506

3.  Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.

Authors:  Carlo Buonerba; Matteo Ferro; Pasquale Dolce; Felice Crocetto; Antonio Verde; Giuseppe Lucarelli; Luca Scafuri; Sergio Facchini; Angelo Vaia; Alfredo Marinelli; Daniela Terracciano; Liliana Montella; Nicola Longo; Ciro Imbimbo; Vincenzo Mirone; Giuseppe Di Lorenzo; Sabino De Placido; Guru Sonpavde
Journal:  Crit Rev Oncol Hematol       Date:  2020-05-23       Impact factor: 6.312

4.  Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004.

Authors:  David M Werny; Trevor Thompson; Mona Saraiya; David Freedman; Benny J Kottiri; Robert R German; Mark Wener
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-12-19       Impact factor: 4.254

Review 5.  Prostate cancer. When to offer screening in the primary care setting.

Authors:  S R Gambert
Journal:  Geriatrics       Date:  2001-01

Review 6.  The emerging role of obesity, diet and lipid metabolism in prostate cancer.

Authors:  Matteo Ferro; Daniela Terracciano; Carlo Buonerba; Giuseppe Lucarelli; Danilo Bottero; Sisto Perdonà; Riccardo Autorino; Alessandro Serino; Francesco Cantiello; Rocco Damiano; Iulia Andras; Sabino De Placido; Giuseppe Di Lorenzo; Michele Battaglia; Barbara A Jereczek-Fossa; Vincenzo Mirone; Ottavio De Cobelli
Journal:  Future Oncol       Date:  2016-09-14       Impact factor: 3.404

Review 7.  New perspectives in the therapy of castration resistant prostate cancer.

Authors:  Pasquale Rescigno; Carlo Buonerba; Joaquim Bellmunt; Guru Sonpavde; Sabino De Placido; Giuseppe Di Lorenzo
Journal:  Curr Drug Targets       Date:  2012-12       Impact factor: 3.465

Review 8.  Imaging prostate cancer: a multidisciplinary perspective.

Authors:  Hedvig Hricak; Peter L Choyke; Steven C Eberhardt; Steven A Leibel; Peter T Scardino
Journal:  Radiology       Date:  2007-04       Impact factor: 11.105

9.  Clinical agreement in the American Society of Anesthesiologists physical status classification.

Authors:  Kayla M Knuf; Christopher V Maani; Adrienne K Cummings
Journal:  Perioper Med (Lond)       Date:  2018-06-19

10.  Does chronic obstructive pulmonary disease increase the risk of prostate cancer? A nationwide population-based study.

Authors:  Wen-Lin Hsu; Hung-Yi Chen; Fung-Wei Chang; Ren-Jun Hsu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-08-22
View more
  10 in total

1.  Deregulation of Cholesterol Homeostasis by a Nuclear Hormone Receptor Crosstalk in Advanced Prostate Cancer.

Authors:  Nianxin Yang; Yatian Yang; Zenghong Huang; Hong-Wu Chen
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

2.  Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies.

Authors:  Jian-Xuan Sun; Chen-Qian Liu; Xing-Yu Zhong; Jin-Zhou Xu; Ye An; Meng-Yao Xu; Jia Hu; Zong-Biao Zhang; Qi-Dong Xia; Shao-Gang Wang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

3.  Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions.

Authors:  Nishi Karunasinghe; Tsion Zewdu Minas; Bo-Ying Bao; Arier Lee; Alice Wang; Shuotun Zhu; Jonathan Masters; Megan Goudie; Shu-Pin Huang; Frank J Jenkins; Lynnette R Ferguson
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

4.  Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature.

Authors:  Felice Crocetto; Erika di Zazzo; Carlo Buonerba; Achille Aveta; Savio Domenico Pandolfo; Biagio Barone; Francesco Trama; Vincenzo Francesco Caputo; Luca Scafuri; Matteo Ferro; Vincenzo Cosimato; Ferdinando Fusco; Ciro Imbimbo; Giuseppe Di Lorenzo
Journal:  Nutrients       Date:  2021-10-23       Impact factor: 5.717

Review 5.  Radiomics in prostate cancer: an up-to-date review.

Authors:  Matteo Ferro; Ottavio de Cobelli; Gennaro Musi; Francesco Del Giudice; Giuseppe Carrieri; Gian Maria Busetto; Ugo Giovanni Falagario; Alessandro Sciarra; Martina Maggi; Felice Crocetto; Biagio Barone; Vincenzo Francesco Caputo; Michele Marchioni; Giuseppe Lucarelli; Ciro Imbimbo; Francesco Alessandro Mistretta; Stefano Luzzago; Mihai Dorin Vartolomei; Luigi Cormio; Riccardo Autorino; Octavian Sabin Tătaru
Journal:  Ther Adv Urol       Date:  2022-07-04

6.  EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms.

Authors:  Pingan Chang; Shenglan Chen; Xiumei Chang; Jiaxi Zhu; Qingsheng Tang; Limin Ma
Journal:  Eur J Med Res       Date:  2022-07-11       Impact factor: 4.981

7.  The Values of Systemic Immune-Inflammation Index and Neutrophil-Lymphocyte Ratio in Predicting Biochemical Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy.

Authors:  Shuo Wang; Xiao Yang; Ziyi Yu; Peng Du; Xinan Sheng; Yudong Cao; Xieqiao Yan; Jinchao Ma; Yong Yang
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

8.  From Cognitive MR-Targeted Fusion Prostate Biopsy to Radical Prostatectomy: Incidence and Predictors of Gleason Grade Group Upgrading in a Chinese Cohort.

Authors:  Huaqing Yan; Yiming Wu; Xiaobo Cui; Sinian Zheng; Peng Zhang; Rubing Li
Journal:  Biomed Res Int       Date:  2022-08-17       Impact factor: 3.246

9.  Comparison of malignancy and spatial distribution between latent and clinical prostate cancer: an 8-year biopsy study.

Authors:  Liang Zhen; Zhou Zhien; Huang Hanzi; Wu Xingcheng; Xiao Yu; Wang Wenze; Zuo Yuzhi; Chen Yuliang; Zhou Yi; Yan Weigang
Journal:  Eur J Med Res       Date:  2022-09-10       Impact factor: 4.981

10.  KIF11: A potential prognostic biomarker for predicting bone metastasis-free survival of prostate cancer.

Authors:  Haoyuan Wang; Sijie Li; Bin Liu; Shufei Wei; Tianyi Wang; Tao Li; Jiahu Lin; Xiaochen Ni
Journal:  Oncol Lett       Date:  2022-07-15       Impact factor: 3.111

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.